Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
NCT03914612Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2019
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in endometrial cancer (EC) comparing Placebo + Paclitaxel + Carboplatin with Pembrolizumab + Paclitaxel + Carboplatin (2 arms). Primary endpoint: Progression-free Survival up to 37.85 months. Started Aug 2019; status: active, not recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03914612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03914612.